The ESCRT-III protein VPS4, but not CHMP4B or CHMP2B, is pathologically increased in familial and sporadic ALS neuronal nuclei
Open Access
- 19 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Neuropathologica Communications
- Vol. 9 (1), 1-9
- https://doi.org/10.1186/s40478-021-01228-0
Abstract
Nuclear pore complex injury has recently emerged as an early and significant contributor to familial and sporadic ALS disease pathogenesis. However, the molecular events leading to this pathological phenomenon characterized by the reduction of specific nucleoporins from neuronal nuclear pore complexes remain largely unknown. This is due in part to a lack of knowledge regarding the biological pathways and proteins underlying nuclear pore complex homeostasis specifically in human neurons. We have recently uncovered that aberrant nuclear accumulation of the ESCRT-III protein CHMP7 initiates nuclear pore complex in familial and sporadic ALS neurons. In yeast and non-neuronal mammalian cells, nuclear relocalization of CHMP7 has been shown to recruit the ESCRT-III proteins CHMP4B, CHMP2B, and VPS4 to facilitate nuclear pore complex and nuclear envelope repair and homeostasis. Here, using super resolution structured illumination microscopy, we find that neither CHMP4B nor CHMP2B are increased in ALS neuronal nuclei. In contrast, VPS4 expression is significantly increased in ALS neuronal nuclei prior to the emergence of nuclear pore injury in a CHMP7 dependent manner. However, unlike our prior CHMP7 knockdown studies, impaired VPS4 function does not mitigate alterations to the NPC and the integral transmembrane nucleoporin POM121. Collectively our data suggest that while alterations in VPS4 subcellular localization appear to be coincident with nuclear pore complex injury, therapeutic efforts to mitigate this pathogenic cascade should be targeted towards upstream events such as the nuclear accumulation of CHMP7 as we have previously described.Funding Information
- National Institute of Neurological Disorders and Stroke (P01NS099114, U54NS091046 and R01NS094239)
- U.S. Department of Defense
- Fidelity Investments
- Amyotrophic Lateral Sclerosis Association
- Robert Packard Center for ALS Research, Johns Hopkins University
This publication has 35 references indexed in Scilit:
- Border Safety: Quality Control at the Nuclear EnvelopeTrends in Cell Biology, 2015
- Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathologyActa Neuropathologica, 2015
- The C9orf72 repeat expansion disrupts nucleocytoplasmic transportNature, 2015
- Surveillance of Nuclear Pore Complex Assembly by ESCRT-III/Vps4Cell, 2014
- Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein HomeostasisNeuron, 2013
- The changing scene of amyotrophic lateral sclerosisNature Reviews Neuroscience, 2013
- Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutationsHuman Molecular Genetics, 2010
- Multiple reprobing of Western blots after inactivation of peroxidase activity by its substrate, hydrogen peroxideAnalytical Biochemistry, 2009
- CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitroHuman Molecular Genetics, 2007
- Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementiaNature Genetics, 2005